A Phase 2, randomized, placebo-controlled, multicenter study to investigate the efficacy and safety of apremilast (CC-10004) for treatment of subjects with active ulcerative colitis. | Crohn’s & Colitis Foundation
Description
To evaluate the clinical efficacy and safety of apremilast (30 mg BID and 40 mg BID), compared with placebo, in subjects with active ulcerative colitis (UC). In addition, apremilast (30 mg BID and 40 mg BID), compared with placebo, is also being studied to evaluate: the onset of clinical effect; th